Ali Khademhosseini

Born in Tehran, he moved with his family to Canada in 1987 and grew up in Toronto. He took his bachelor's (1999) and master's (2001) degrees in chemical engineering at the University of Toronto, working in the laboratories of Michael Sefton and Peter Zandstra, and his doctorate in bioengineering at MIT in 2005 under Robert Langer. ¹

He was a faculty member at Harvard Medical School and the Wyss Institute from 2005 to 2017, then a professor at UCLA, where he directed the Center for Minimally Invasive Therapeutics, and afterwards chief executive of the Terasaki Institute for Biomedical Innovation in Los Angeles; he has since co-founded a company in AI and science. His roughly one thousand papers include foundational work on GelMA hydrogels, organ-on-a-chip platforms with integrated sensors, surgical sealants and smart wound patches. He co-founded Obsidio, whose embolic technology was acquired by Boston Scientific in 2022, and founded the cultivated-meat company Omeat. The English infobox lists the Mustafa Prize among his awards. ^{1 2}

His faith is recorded as unknown, on absence of attestation: no article text, category filing or Wikidata value names a religion for him, and the Mustafa Prize listing in his awards — a prize listing, not a statement of affiliation — is the nearest any source comes. ^{1 2 3}

• The defined source entities cited above, recorded in data/source/.
• Revisions of this article must be dated, and must name the source that changed each fact.